Suboxone (Buprenorphine): How It Works, Tapering, and Recovery Support

Suboxone (buprenorphine and naloxone) is a medication for opioid use disorder, and most people who find this page are on it, or love someone who is, and have been told it is "just another addiction." It is not. In 2022 an estimated 9.4 million American adults needed treatment for opioid use disorder, and only 25.1 percent received a medication for it (CDC MMWR, 2024). The bigger problem is people who never start. Buprenorphine is still an opioid, though: the body adapts to it, and stopping without a plan carries real risk. This page covers how it works, why dependence on it is expected, what withdrawal and tapering look like when you and your prescriber decide it is time, and how support at home fits alongside it.

What Suboxone is and how it works

Suboxone is a sublingual film indicated "for treatment of opioid dependence" (Suboxone prescribing information, section 1). It comes in 2, 4, 8, and 12 mg strengths of buprenorphine, each paired with a quarter as much naloxone, and the recommended maintenance target is 16 mg/4 mg a day (section 2.4). Zubsolv is the same combination in a better-absorbed tablet, so its 5.7 mg/1.4 mg tablet matches "one Suboxone 8 mg/2 mg sublingual tablet" (Zubsolv prescribing information); buprenorphine alone, once branded Subutex, is a generic tablet. Two long-acting injections, Sublocade (monthly) and Brixadi (weekly or monthly), are given to people "who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine" (Sublocade prescribing information, section 1; Brixadi, section 1). Members call the films "strips," "subs," or "bupe."

The pharmacology is what makes it a treatment rather than a substitute. "Buprenorphine is a partial agonist at the mu-opioid receptor." Partial means it turns the receptor on part way and then stops: its effects are "limited by a ceiling effect," and in the studies "there was a dose that produced no further effect" (sections 12.1 and 12.2). The result, in SAMHSA's words, is "less potential to cause respiratory depression" (SAMHSA TIP 63, Part 3). It also binds tightly, so it blocks most of the effect of heroin or fentanyl taken on top of it. The cravings and the sickness stop, the high does not come back, and a person gets their days back. The naloxone is there for a narrow reason: under the tongue it is barely absorbed, but injected it is, and the label says it "may deter injection." It is not what makes the medication work.

Two more facts shape everything that follows. Buprenorphine is long-acting, with a "mean elimination half-life ranging from 24 to 42 hours" (section 12.3), against three to four hours for oxycodone, which is why one daily dose holds. Sublocade stretches that to "43 to 60 days" (Sublocade, section 12.3). And it is a Schedule III controlled substance, a category the DEA defines as "drugs with a moderate to low potential for physical and psychological dependence" (DEA). Since 2023, no special waiver is needed to prescribe it (SAMHSA); any prescriber with an ordinary DEA registration can.

Dependence on buprenorphine is expected; that is not the same as addiction

Start with the label, because it settles the argument. "Chronic administration produces physical dependence of the opioid type, characterized by moderate withdrawal signs and symptoms upon abrupt discontinuation or rapid taper. The withdrawal syndrome is typically milder than seen with full agonists and may be delayed in onset" (section 9.3). Dependence is a body that has adapted to a daily medication, the way it does to blood pressure pills and antidepressants.

Addiction is different in kind. TIP 63 explains that it "is more than physical dependence. Addiction changes the reward circuitry of the brain, affecting cognition, emotions, and behavior" (SAMHSA TIP 63, Part 1). The behaviors that define it, the lying, the money, the day organized around getting more, are what a stable dose takes away. That is why the same document states, without hedging, "Patients taking medication for OUD are considered to be in recovery."

Families ask how long. TIP 63 answers: "Arbitrary time limits on the duration of treatment with OUD medication are inadvisable" (TIP 63, Part 1), and "Patients should take buprenorphine as long as they benefit from it and wish to continue," because there is "no known duration of therapy" after which stopping is safe (TIP 63, Part 3). The American Society of Addiction Medicine agrees: "There is no recommended time limit" (ASAM, 2020). Our position follows the evidence. Medication is recovery, and our coaches never pressure anyone off it.

Signs the plan needs a second look

None of these mean Suboxone is failing; they mean the plan around it needs attention. Doses get missed, first now and then, then for days, usually because the person feels fine. The film runs out early, which can mean the dose is too low or that some of it is going elsewhere. Extra strips are being bought; the DEA reports that diversion and misuse of buprenorphine "have increased" since 2003 (DEA, 2026). Benzodiazepines or heavy drinking have crept in. Or fentanyl is being used on top, which often shows up first as a test result. Any one of these is a conversation with the prescriber. Several together are a reason to raise the dose or the support, not to stop the medication.

Why stopping Suboxone on your own is the risky part

Buprenorphine withdrawal itself is rarely dangerous; the WHO says opioid withdrawal "is not usually life-threatening" (WHO, 2009). The danger comes after. When the medication stops, tolerance falls, the receptor blockade lifts, and the street supply is fentanyl. The WHO says everyone who has withdrawn from opioids is "at increased risk of overdose due to reduced opioid tolerance," and SAMHSA's overdose toolkit lists "using drugs after a recent period of abstinence, which may decrease previous tolerance levels" among its leading risk factors (SAMHSA, 2023). TIP 63 is direct: "most patients with OUD who undergo medically supervised withdrawal will start using opioids again," and those who complete it "are at risk of opioid overdose" (TIP 63, Part 1). ASAM wants anyone who discontinues buprenorphine told about "the increased risk of death if they return to illicit opioid use" (ASAM, 2020).

The flip side happens at the start. Because buprenorphine grips the receptor harder than a full opioid while activating it less, taking it too soon after fentanyl throws the other drug off and produces sudden, severe withdrawal. The label warns that it "may precipitate opioid withdrawal signs and symptoms" if given "before the agonist effects of the opioid have subsided," and directs that the first dose wait for "objective signs of moderate opioid withdrawal," at least six hours after the last use (sections 5.10 and 2.3). Fentanyl stretches that wait, and a bad first day is the most common reason members tell us they gave up on Suboxone the first time. The fix is a prescriber who knows how to start it.

What buprenorphine withdrawal and tapering look like

The long half-life changes the shape of withdrawal: it "may be delayed in onset" and is "typically milder" (section 9.3). The WHO gives the pattern for long-acting opioids as "Onset of opioid withdrawal symptoms 12-48 hours after last use; duration 10-20 days," roughly double the short-acting figures (WHO, 2009). After an injection it is slower still. Everyone differs. This is the general shape after an abrupt stop, which is what we are trying to help you avoid.

Days 1 to 2

Often nothing much, which is the trap: a missed day feels manageable, and people decide they were "over it." Yawning, restlessness, anxiety, and a mild ache arrive late on day one or during day two.

Days 3 to 7

This is the peak: sweats and chills, aches, stomach cramps, diarrhea, insomnia, and a low mood that feels bottomless. It is milder than fentanyl withdrawal and lasts longer, and that combination wears people down. This is where "just a little to sleep" happens, and why a plan for these nights matters more than resolve.

Weeks 2 and 3

The physical symptoms fade slowly rather than switching off. Sleep is still broken, and cravings attach to the situations the medication used to hold steady: a bad shift, a fight at home, the drive past the old exit.

Weeks 4 and beyond

Mood, sleep, and motivation can lag for weeks. Tolerance is now well below where it was, and this stretch is where a return to use is most likely to be fatal. TIP 63 says that if someone returns to use "it may be appropriate for them to restart buprenorphine or switch to methadone or XR-NTX treatment" (TIP 63, Part 3). Restarting is the plan working.

How a taper works when you and your prescriber decide it is time

Some people do reach a point where coming off makes sense, and TIP 63 is clear whose call it is: "It is up to patients to decide whether to taper or eventually discontinue medication" (TIP 63, Part 3). It also describes who tends to do well: people with "sustained abstinence from opioids and other drugs, psychosocial support, housing, effective coping strategies, stable mental health, employment." That is a checklist, not a gate, and most of it is what a coach helps build.

The pace is slow. "There is no ideal tapering protocol," but "Generally, taper occurs over several months," and people should be told "that they can stop the taper at any time" (TIP 63, Part 3); the label says only to "gradually taper to avoid signs and symptoms of withdrawal" (section 2). In practice the last 2 mg take longer than the first 14, and pausing at a dose for a month is normal.

Two tools make the end of a taper safer. The first is an extended-release injection: Sublocade's levels fall over months, and people coming off it "may have detectable plasma and urine levels of buprenorphine for twelve months or longer" (Sublocade, section 12.3), which turns the cliff into a slope. The second is naltrexone, the blocker; TIP 63 describes "the role of XR-NTX in preventing return to opioid use" after an agonist, and puts "a naloxone kit" in every taper safety plan (TIP 63, Part 3). Narcan 4 mg nasal spray has been sold over the counter since March 29, 2023 (FDA). Keep it in the house through the taper and for months after.

Suboxone with alcohol, benzodiazepines, or other opioids

The ceiling effect protects people from buprenorphine alone, not from combinations. The label warns that "Life-threatening respiratory depression and death have occurred," mostly with "misuse by self-injection" or "the concomitant use of buprenorphine and benzodiazepines or other CNS depressants, including alcohol" (section 5.2).

What the warning does not say is "take them off Suboxone." In September 2017 the FDA issued a safety communication because prescribers were doing exactly that. It states that "the harm caused by untreated opioid addiction can outweigh these risks," and that buprenorphine and methadone "should not be withheld from patients taking benzodiazepines" (FDA, 2017). That language is now in the label: treatment "should not be categorically denied to patients taking these drugs," since barriers to treatment "can pose an even greater risk of morbidity and mortality due to the opioid use disorder alone," and "Cessation of benzodiazepines or other CNS depressants is preferred" (section 5.3). ASAM agrees that sedative use "should not be a reason to withhold or suspend treatment with methadone or buprenorphine" (ASAM, 2020). If you are on Suboxone and a benzodiazepine, the conversation is about the benzodiazepine.

Fentanyl on top of a full dose usually does little, because the receptor is occupied. Fentanyl after a few missed days is the dangerous case. Overdose deaths fell from 105,007 in 2023 to 79,384 in 2024 (CDC, 2026); wider access to buprenorphine is part of that story.

Drug testing for buprenorphine

Buprenorphine does not show up on a standard opiate screen. The American College of Medical Toxicology's practice statement says that "Separate assays are required to reliably detect buprenorphine, fentanyl, fentanyl analogs, hydrocodone, methadone" and the other synthetic opioids (ACMT, 2021). A workplace five-panel will not see it, which also means it will not confirm you are taking it. Prescribers test for it on purpose: TIP 63 lists "Testing urine for buprenorphine and norbuprenorphine" among the ways to confirm the medication is being taken (TIP 63, Part 3). Norbuprenorphine matters because the body makes it; its presence shows the film was absorbed, not dipped in the cup.

Saliva windows for buprenorphine are less settled than urine windows. In one study of 260 paired samples from people in treatment, urine was positive in 97 percent of those prescribed buprenorphine and oral fluid in 78 percent (Ransohoff et al., Drug Alcohol Depend, 2019). So a single negative saliva result is not proof of a missed dose; timing and the lab's cutoff both matter, and we read it alongside the member's account and the prescriber's records rather than quoting one number for everyone.

Our members use saliva-based screening that is assigned at random through the week. Buprenorphine has its own line on the instant 10-panel strip we use, and the lab-confirmed oral fluid test reports buprenorphine and norbuprenorphine at a 0.5 ng/mL cutoff and naloxone at 2 ng/mL. A member on Suboxone tests positive, as expected, and that result confirms adherence. That is the point of the test, not a problem with it. The same lab panel reports fentanyl, oxycodone, morphine, methadone, and the other opioids as separate lines, so it also shows whether anything else is on board. You do not choose whether you test; you choose who sees the results, usually the prescriber and, if you want, a spouse or parent. We explain the details in our guide to how sobriety monitoring works.

How recovery on Suboxone works with Accountable

We are not a detox and we do not prescribe. The Suboxone belongs to your prescriber, and any decision to change it belongs to you and them. What we provide is the support around it, at home, for as long as you want it. Nobody here will ask when you plan to get off it.

1. Get the full picture

In the first sessions your coach maps what is actually going on: your dose and whether it holds you all day, how starting went, whether alcohol or benzodiazepines are in the picture, and whether anything has been used on top. If you have no prescriber, or yours is pushing a taper you did not ask for, we help you find one, and with your permission we coordinate so everyone works from the same plan.

2. Build a plan that fits your life

The plan is built around the real calendar: how the refill gets filled before a holiday weekend, what you do when a pharmacy is out of stock, who you text when an old contact texts you, and what a surgery means for your dose (a call to the prescriber, not a skipped day). Daily peer group meetings and a weekly family Zoom group give the people around you their own place to get support, and to hear other families say that medication is recovery.

3. Weekly check-ins through the long stretch

The dangerous moment on buprenorphine is usually quiet: feeling fine, missing a few days, deciding it is time. Your coach shows up every week, and the saliva screening turns "I think he's still taking it" into a shared record that you control. When a slip happens, we treat it as information: the plan changes, the support goes up, we make sure naloxone is in the house, and if the medication has stopped, the first goal is getting back on it. Every coach at Accountable has their own recovery behind them; some have been on this medication.

Accountable is covered by a growing list of commercial health plans, with more added each month, and private-pay plans start at $375 per month. You can check your coverage in a few minutes or call the care team at (646) 450-7641. Families are welcome to make the first call; see our page for families.

Common questions

Is Suboxone just replacing one addiction with another?

No. Buprenorphine produces physical dependence, which the label expects and calls "moderate" (section 9.3). Addiction "is more than physical dependence," and SAMHSA states that "Patients taking medication for OUD are considered to be in recovery" (TIP 63, Part 1). A stable dose removes the craving and the chaos; it does not produce a high.

How long should I stay on Suboxone?

As long as it helps. SAMHSA says "Arbitrary time limits on the duration of treatment with OUD medication are inadvisable" (TIP 63, Part 1), and ASAM says "There is no recommended time limit for pharmacological treatment" (ASAM, 2020). Years is common.

Will Suboxone show up on a drug test?

Only if the test looks for it, and standard opiate panels do not. Our instant strip and our lab test both include it, so a member on Suboxone tests positive as expected. With a half-life of 24 to 42 hours (section 12.3), it stays detectable for days after the last film, and for months after a Sublocade injection (Sublocade, section 12.3).

Can I overdose on Suboxone?

In an adult with opioid tolerance, rarely on its own. Deaths have occurred, mostly with injection or with "benzodiazepines or other CNS depressants, including alcohol" (section 5.2). Children are the exception: it "can cause severe, possibly fatal, respiratory depression in children," so films stay locked up (section 5.4). If anyone will not wake up, call 911 and give naloxone, which does "not cause harm if given to a person who is not experiencing opioid overdose" (SAMHSA, 2023).

What if I run out of Suboxone?

Call your prescriber or the pharmacy the same day, and tell your coach. The long half-life gives you a cushion; the WHO puts withdrawal onset for long-acting opioids at 12 to 48 hours (WHO, 2009). Do not fill the gap with a strip from a friend or with anything else; after several days off, tolerance is lower than you think, and naloxone should be within reach.

Sources

• U.S. Food and Drug Administration. Suboxone (buprenorphine and naloxone) sublingual film, prescribing information, revised December 2025.

• U.S. Food and Drug Administration. Sublocade (buprenorphine extended-release) injection, prescribing information, revised February 2025.

• U.S. Food and Drug Administration. Brixadi (buprenorphine) extended-release injection, prescribing information, revised December 2025.

• U.S. Food and Drug Administration. Zubsolv (buprenorphine and naloxone) sublingual tablets, prescribing information, revised December 2025.

• U.S. Food and Drug Administration. FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants. Drug Safety Communication and podcast, September 20, 2017.

• U.S. Food and Drug Administration. FDA Approves First Over-the-Counter Naloxone Nasal Spray. Press announcement, March 29, 2023.

• Drug Enforcement Administration, Diversion Control Division. Buprenorphine, drug and chemical information sheet, July 2026.

• Drug Enforcement Administration. Drug Scheduling.

• Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder, Part 1: Introduction to Medications for Opioid Use Disorder Treatment. 2021 update, NCBI Bookshelf.

• Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder, Part 3, Chapter 3D: Buprenorphine. 2021 update, NCBI Bookshelf.

• Substance Abuse and Mental Health Services Administration. Overdose Prevention and Response Toolkit. PEP23-03-00-001, 2023.

• Substance Abuse and Mental Health Services Administration. Waiver Elimination (MAT Act).

• American Society of Addiction Medicine. Executive Summary of the Focused Update of the ASAM National Practice Guideline for the Treatment of Opioid Use Disorder. 2020.

• World Health Organization. Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Settings, chapter 4: Withdrawal Management. 2009, NCBI Bookshelf.

• Centers for Disease Control and Prevention. Dowell D, et al. Treatment for Opioid Use Disorder: Population Estimates, United States, 2022. MMWR, June 27, 2024.

• Centers for Disease Control and Prevention, National Center for Health Statistics. Garnett MF, Miniño AM. Drug Overdose Deaths in the United States, 2023-2024. NCHS Data Brief No. 549, January 2026.

• Stolbach AI, Connors NJ, Nelson LS, Kulig K. ACMT Practice Statement: Interpretation of Urine Opiate and Opioid Tests. American College of Medical Toxicology, September 13, 2021.

• Ransohoff JR, Petrides AK, Piscitello GJ, Flood JG, Melanson SEF. Urine is superior to oral fluid for detecting buprenorphine compliance in patients undergoing treatment for opioid addiction. Drug and Alcohol Dependence. 2019.